Guardant Health Price Target Raised to $200.00/Share From $190.00 by Guggenheim
Guggenheim has raised its price target for Guardant Health (NASDAQ:GH) shares to $200.00 from $190.00. This adjustment reflects an increased valuation for the company's stock by the financial institution. The new price target suggests a continued positive outlook from Guggenheim on Guardant Health's future performance.
Asset turnover of Guardant Health, Inc. – HAN:5GH
This article focuses on the asset turnover of Guardant Health, Inc. (HAN:5GH) as presented on TradingView. It appears to be a financial data page rather than an analytical article, showing the company's performance on the Hannover Stock Exchange. The content mainly lists navigation and legal disclaimers, with the core financial data element being "Asset turnover of Guardant Health, Inc. Period Value Change Change %".
Total liabilities of Guardant Health, Inc. – HAN:5GH
This article provides a brief financial snippet for Guardant Health, Inc. (HAN:5GH), specifically focusing on its total liabilities. It indicates the stock is listed on the Hannover Stock Exchange and is currently closed with no trades. The core content is a single line stating "Total liabilities of Guardant Health, Inc. Period Value Change Change %".
Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Guardant Health (GH) has seen its stock increase fivefold over the past three years, prompting questions about whether its current valuation is supported by future cash flows. The company's recent expansion of coverage for its Shield blood test is expected to boost future cash inflows significantly, with analysts forecasting a move from current cash burning to substantial free cash generation by the early 2030s, which could justify its current share price of $177.25. However, there are differing views, with some narratives suggesting the stock is undervalued by 9% due to AI integration, while others indicate it could be overvalued by 17% due to reimbursement challenges.
Guardant Health co-CEO Helmy Eltoukhy on breast cancer test
Guardant Health co-CEO Helmy Eltoukhy appeared on CNBC's 'Squawk on the Street' to discuss their breast cancer test. The discussion centered on the ability to manage cancer using a blood test.
Guardant Health (GH) Rides Liquid Biopsy Growth Narrative With Valuation Still In Focus
Guardant Health (GH) has seen a significant share price increase of 73.4% year-to-date, driven by the growing adoption of non-invasive blood-based cancer diagnostics. Despite a strong performance and analyst estimates suggesting it's 9% undervalued with a fair value of $194 per share, the company faces challenges including ongoing losses and a high P/S ratio of 20x compared to industry averages. This valuation gap raises questions about whether the projected growth justifies the current premium investors are paying.
How FDA Approval Has Changed The Investment Story At Guardant Health Stock
Guardant Health (NasdaqGS:GH) recently secured FDA approval for Guardant360 CDx as the first liquid biopsy companion diagnostic for longitudinal testing in advanced or metastatic breast cancer, alongside showcasing 20 abstracts at WCLC 2026 highlighting its liquid biopsy and methylation-based lung cancer research. This clinical integration of its tests across treatment selection and earlier cancer detection workflows is poised to shift Guardant Health’s investment narrative. While the near-term still focuses on growing test volumes against ongoing losses, the new FDA approval strengthens the clinical adoption thesis, with analysts forecasting significant revenue and earnings growth by 2029.
Form 4 Guardant Health Inc For: 22 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Guardant Health Inc. on September 22. It mentions the company's stock symbol GH and includes various market data and other trending news headlines, but no specific details about the Form 4 itself are provided within the body of the text.
Form 4 Guardant Health Inc For: 22 September By Investing.com
The article is a brief announcement from Investing.com regarding a Form 4 filing for Guardant Health Inc. on September 22, 2026. It mentions Guardant Health Inc. (GH) with a stock movement of -0.48% and includes links to view comments. The content primarily consists of navigational elements and market data, with the core article being a short informational note.
Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside Potential
Guardant Health, Inc. (GH) is positioned as a strong buy in the diagnostics and research industry, specializing in cancer diagnostics with a market capitalization of $24.07 billion. Despite a lack of traditional P/E ratios, the company's impressive revenue growth of 44.30% and positive analyst sentiment with a 9.16% upside potential highlight its robust growth trajectory. Guardant Health's strategic reinvestment in R&D and diverse portfolio of tests like Guardant360 CDx underscore its commitment to advancing personalized medicine and cancer treatment.
Guardant Health (NASDAQ: GH) director moves to sell 6,674 shares
Guardant Health director Steve E. Krognes has filed a Rule 144 notice to potentially sell 6,674 shares of the company's common stock, valued at approximately $1.17 million. These shares were acquired as equity compensation on June 12, 2025, through a restricted stock lapse. The proposed sale is anticipated to occur around September 16, 2026, on NASDAQ.
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health announced that its Shield™ blood test for colorectal cancer screening will be covered by Carelon Healthcare Services' clinical guidelines starting November 15, 2026. This expansion increases the total covered lives for Shield to approximately 90 million, or 75% of eligible U.S. patients aged 45 and older. The FDA-approved Shield test offers a more accessible screening option, addressing rising colorectal cancer rates, especially in younger adults.
Cathie Wood’s ARK increases stake in Guardant Health stock
Cathie Wood's ARK ETFs increased their stake in Guardant Health (NASDAQ:GH) on September 17, 2026, purchasing 7,738 shares valued at over $1.35 million. This continues ARK's trend of accumulating shares in Guardant Health and reflects their focus on the healthcare and biotechnology sectors. ARK also acquired a small number of Scribe Therapeutics (SCTX) shares while divesting from Brera Holdings PLC (SLMT) across several ETFs.
Patrick Dempsey Is the New Face of Guardant Health’s ‘The Reckoning’ Campaign
Patrick Dempsey is spearheading Guardant Health's new multi-million dollar "The Reckoning" campaign, urging early colorectal cancer screening with Guardant's Shield™ blood test. The campaign highlights the rising death toll from colorectal cancer, particularly among younger adults, and promotes Shield™ as the first FDA-approved primary blood test for screening. Dempsey, a long-time cancer advocate, aims to reduce screening barriers and honor those affected by the disease.
Guardant Health stock hits 52-week high at 176.68 USD
Guardant Health Inc.'s stock reached a new 52-week high of $176.68, reflecting a remarkable 216.17% increase over the past year. This surge is attributed to strong investor confidence, positive market sentiment, and advancements in cancer diagnostics. Recent analyst reports from Stifel, TD Cowen, Piper Sandler, Bernstein, and Rothschild Redburn have reinforced a "Buy" or "Overweight" rating, raising price targets based on impressive Q2 revenue growth and the potential of their Shield and G360 products.
Guardant Health stock hits 52-week high at 176.68 USD By Investing.com
Guardant Health (NASDAQ: GH) stock reached a new 52-week high of $176.68, reflecting a 216.17% surge over the past year. This growth is attributed to strong Q2 revenue of $335 million, exceeding expectations, and positive analyst ratings with increased price targets due to advancements in cancer diagnostics and product growth. The company's recent FDA approval for its Shield colorectal cancer screening blood test further fuels investor confidence.
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health's Shield blood test for colorectal cancer screening will be covered by EviCore by Evernorth, significantly expanding access for eligible policyholders aged 45 and older. This coverage increases the total number of insured lives for Shield to approximately 94 million, marking rapid commercial adoption for the FDA-approved blood test. The move aims to make CRC screening more accessible, especially as colorectal cancer rates rise in younger adults.
EviCore expands coverage for Guardant’s Shield cancer test
EviCore, a subsidiary of Cigna and the second-largest specialty benefits manager in the U.S., will expand coverage for Guardant Health Inc.'s Shield blood test for colorectal cancer screening starting January 1, 2027. This expansion increases the total covered lives for Shield to approximately 94 million, applying to individuals aged 45 and older at average risk for colorectal cancer. Guardant's Shield test is FDA-approved, included in major cancer guidelines, and has been performed over 200,000 times in real-world settings.
Guardant Health director plans $20,300 share sale | GH SEC Filing - Form 144
Guardant Health director Musa Tariq has filed a Rule 144 notice to sell 116 shares of GH common stock, valued at $20,300, derived from equity compensation. This filing indicates a neutral impact and sentiment. Over the past three months, Tariq has sold several hundred thousand dollars worth of Guardant Health common stock in previous transactions.
Cigna-owned EviCore will cover Guardant's blood test for colorectal cancer starting Jan. 1, 2027.
Guardant Health's Shield blood test for colorectal cancer screening will be covered by EviCore by Evernorth, a Cigna-owned company, starting January 1, 2027. This decision significantly expands the test's commercial reach, increasing total covered lives to approximately 94 million, representing the majority of eligible patients in the U.S. Shield is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults and is recommended by the American Cancer Society and National Comprehensive Cancer Network.
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health and its collaborators will present 20 abstracts at the 2026 World Conference on Lung Cancer, showcasing advances in liquid biopsy tests for lung cancer. The presentations will cover early detection, treatment management, molecular residual disease surveillance, and resistance research. Guardant Health will also sponsor a symposium on the clinical interpretation of plasma-based methylation signals in advanced NSCLC.
Rothschild Redburn initiates Guardant Health stock with buy rating
Rothschild Redburn has initiated coverage on Guardant Health Inc. (NASDAQ:GH) with a Buy rating and a price target of $203.00, citing the company's leadership in liquid biopsy testing. The firm highlighted Guardant Health's products like Shield (colorectal cancer screening), Guardant360 (tumor sequencing), and Reveal (minimal residual disease test) as key growth drivers. This positive outlook follows strong second-quarter earnings for Guardant Health, with 44% revenue growth and subsequent price target increases from several other analyst firms.
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
Guardant Health announced that its Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. This approval marks a significant shift towards early detection of resistance mutations via ctDNA testing, allowing for adaptive cancer management before radiographic progression. The SERENA-6 trial demonstrated that this approach reduced the risk of disease progression or death by 56% when patients switched to camizestrant-based treatment after an ESR1 mutation was detected.
Carelon Adds Coverage for Guardant Health’s Shield Colorectal Cancer Blood Test
Carelon Healthcare Services has expanded its clinical guidelines to include coverage for Guardant Health's Shield blood test for colorectal cancer screening, effective November 15. This update increases the total covered lives for the Shield test to approximately 90 million, representing about 75% of eligible patients in the US. The Shield test is an FDA-approved blood-based screening test for average-risk adults aged 45 and older and is recommended by major cancer organizations.
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health announced that its Shield blood test for colorectal cancer screening will be covered by Carelon Health Services starting November 15. This expansion by one of the largest national medical benefit managers increases the total covered lives for Shield to approximately 90 million, significantly improving access to this FDA-approved blood test for eligible individuals aged 45 and older. The Shield test is recognized for its high performance in CRC detection and adherence rates, addressing rising colorectal cancer rates, particularly in younger adults.
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health announced that its Shield blood test for colorectal cancer screening will be covered by Carelon Healthcare Services starting November 15, significantly expanding access to approximately 90 million eligible Americans. This FDA-approved blood test offers a more accessible screening option for individuals aged 45 and older, especially crucial as colorectal cancer rates rise in younger adults. The coverage by Carelon, a major medical benefit manager, marks a critical step in Guardant Health's mission to make CRC screening more widely available.
Guardant Health ordered to pay $245M in patent dispute
Guardant Health has been ordered by a U.S. district court to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for willfully infringing patents related to DNA sequencing technology. The judgment includes damages, accrued royalties, and interest, along with ongoing 6% royalties on sales of 11 products and services until 2033. Guardant Health plans to appeal the decision, maintaining that it did not infringe the patents and has made design improvements to avoid future royalties.
US Court to pharma giant Guardant Health: You willfully infringed patents for cancer-testing; asked to pa
A federal judge has ordered Guardant Health to pay over $245 million to TwinStrand Biosciences and the University of Washington for willfully infringing on patented DNA sequencing technology, 'Duplex Sequencing.' The ruling also mandates a 6% royalty on covered Guardant products until 2033. Guardant Health plans to appeal the decision, asserting confidence in its intellectual property and arguing that many products covered by the ruling have been discontinued or upgraded, making current versions exempt from royalties.
Guardant Health Ordered to Pay $245 Million in DNA Sequencing Patent Case
A Delaware federal judge has finalized a ruling requiring Guardant Health to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for infringing on two Duplex Sequencing patents. The award includes an $83.4 million jury verdict, additional damages, accrued royalties, and interest, with ongoing quarterly royalty payments mandated until 2033. Guardant Health plans to appeal the decision, asserting that many affected products have been discontinued or upgraded, while its shares fell 3.6% on the news.
Final judgement favours TwinStrand in Guardant patent case
The US District Court for the District of Delaware has issued a final judgment in favor of TwinStrand Biosciences and the University of Washington in their patent infringement lawsuit against Guardant Health, Inc. The judgment upholds a November 2023 jury verdict, finding Guardant Health willfully infringed two core patents related to TwinStrand's Duplex Sequencing technology. TwinStrand and the University of Washington have been awarded over $245.2 million in damages, accrued royalties, and interest, with a continued 6% royalty ordered for future sales.
TwinStrand, UW awarded $245 million in patent infringement suit
Seattle-based TwinStrand Biosciences and the University of Washington have been awarded $245 million in a patent infringement lawsuit against Guardant Health. The lawsuit, filed in 2021, centered on technology invented by Jesse Salk, who later spun out TwinStrand from UW in 2015. This legal victory highlights the value of the underlying technology developed at UW and commercialized by TwinStrand.
Guardant Health loses patent judgment; ordered to pay $245M
Guardant Health (GH) has been ordered to pay $245 million after a Delaware federal court ruled in favor of TwinStrand BioSciences and the University of Washington. The judgment stems from a patent infringement case where Guardant was accused of using TwinStrand's Duplex Sequencing technology. This final judgment combines an $83.4 million jury award with additional damages, including supplemental damages and pre- and post-judgment interest.
Guardant Health to Appeal Federal District Court Judgment
Guardant Health (GH) announced its decision to appeal a federal district court judgment concerning intellectual property claims brought by TwinStrand Biosciences and the University of Washington. The company asserts that its current Guardant Reveal and Shield products, along with improvements to Guardant360, are excluded from potential royalties due to technological updates. Guardant Health remains confident it will prevail on appeal, noting preliminary invalidation of TwinStrand's patents in separate challenges.
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
A Delaware federal judge has ordered Guardant Health (NASDAQ: GH) to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for willfully infringing on two Duplex Sequencing patents. This penalty covers 11 products and services, constituting about 90% of Guardant Health's revenue during the period. The court also mandated ongoing 6% royalties on the contested products until the patents expire in March 2033, alongside quarterly accounting reports and continued interest accrual on unpaid balances.
U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute
A U.S. court has ordered Guardant Health to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for infringing patents related to DNA sequencing technology. The judgment includes damages, accrued royalties, and interest, covering Guardant's products that accounted for approximately 90% of its revenue during the infringement period. TwinStrand's Duplex Sequencing technology, developed at the University of Washington, is used in cancer research and diagnostics.
TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
TwinStrand Biosciences has been awarded over $245.2 million in damages, accrued royalties, and interest in a patent infringement suit against Guardant Health. The judgment, entered by the U.S. District Court for the District of Delaware, upholds a November 2023 jury verdict finding Guardant Health willfully infringed two core patents related to TwinStrand's Duplex Sequencing technology. Guardant Health is also ordered to pay a 6% royalty on sales of 11 infringing products and services until the patents expire in 2033.
Court orders Guardant Health to pay $245.2M in patent case
A U.S. District Court in Delaware has ordered Guardant Health Inc. to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for patent infringement. The judgment upholds a November 2023 jury verdict that found Guardant Health willfully infringed on two patents related to TwinStrand’s Duplex Sequencing technology across 11 of its products and services. The total award includes damages, supplemental damages, accrued royalties, and pre-judgment and post-judgment interest, along with a mandated 6% royalty on future sales of the infringing products until the patents expire.
Guardant Health (NASDAQ: GH) insider plans more sales after June disposals
Guardant Health (NASDAQ: GH) officer AmirAli Talasaz has filed a Rule 144 notice to sell up to 37,500 shares of common stock, valued at approximately $6.3 million. These shares were acquired in 2018 as founder shares. This planned sale follows two significant disposals in June 2026, totaling over 250,000 shares, which generated combined proceeds exceeding $39 million.
Ninepoint Partners LP Makes New Investment in Guardant Health, Inc. $GH
Ninepoint Partners LP recently acquired 19,018 shares of Guardant Health, Inc. valued at approximately $2.85 million during the second quarter. This new investment comes as institutional investors collectively own 92.6% of the company, and Guardant Health has reported better-than-expected quarterly results with significant revenue growth. Despite insider share sales by the CEO and a director, analysts maintain a "Moderate Buy" consensus rating with an average price target of $183.78 for the stock.
Lisanti Capital Growth LLC Takes $1.59 Million Position in Guardant Health, Inc. $GH
Lisanti Capital Growth LLC has acquired a new stake of 10,610 shares in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, valued at approximately $1.59 million. This move is part of a broader trend of institutional investment in Guardant Health, with several other large investors also either adding to or initiating positions in the company. Despite significant insider selling activity, analysts have largely maintained "buy" or "outperform" ratings, with an average price target of $183.78 for the stock.
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH
MSH Capital Advisors LLC initiated a new position in Guardant Health (NASDAQ:GH) during the second quarter, acquiring 6,242 shares valued at approximately $936,000. Institutional investors now collectively own 92.60% of the company, though insiders have recently sold a significant number of shares. Despite insider sales, analysts maintain a "Moderate Buy" rating with an average price target of $183.78, supported by the company's strong Q2 revenue growth of 44.3% year-over-year.
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH
Eagle Health Investments LP has acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, purchasing 300,685 shares valued at approximately $45.11 million. This investment makes Guardant Health the third-largest position in Eagle Health Investments LP's portfolio, comprising 7.5% of its holdings. Other institutional investors also initiated new stakes in Guardant Health, while company insiders, including Chris Freeman and CEO Amirali Talasaz, sold significant shares.
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance
Guardant Health (GH) has seen significant advancements with FDA approval for its Guardant360 test and inclusion of its Shield colorectal cancer screening test in American Cancer Society guidelines. These developments indicate growing acceptance of Guardant's blood-based cancer tests, influencing its investment narrative positively. While these milestones support broader adoption, the company still faces challenges related to cash burn and potential future financing needs.
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC
Perigon Wealth Management LLC has acquired 7,149 shares of Guardant Health, Inc. (NASDAQ:GH), valued at approximately $1.07 million, contributing to institutional investors owning 92.6% of the company. Despite significant insider selling totaling over $80 million, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $183.78, following Guardant Health's strong quarterly revenue growth and narrower-than-expected loss.
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock
Guardant Health (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company's stock for $18,148.20 on August 17th, reducing his stake by 1.01%. This transaction occurred under a pre-arranged Rule 10b5-1 plan. The company's shares traded down 1.0% to $160.12, despite beating analyst expectations for its latest quarterly revenue and adjusted loss per share, and analysts generally maintain a "Moderate Buy" rating for the stock.
How Guardant aims to expand cancer screening with a blood test
Guardant Health is making strides in early cancer detection with its Shield blood test for colorectal cancer, which gained FDA approval in 2024 and is being covered by UnitedHealthcare. The company is actively working to improve the test's sensitivity, particularly for early-stage cancers and precancerous lesions, and is expanding its application to multicancer detection. Guardant aims to eventually pursue FDA approval for its multicancer test, building on its current status as a lab-developed test gathering real-world evidence.
Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test
Guardant Health (GH) has re-entered investor focus following Q2 2026 developments, including FDA approval for its Guardant360 liquid biopsy test and American Cancer Society support for its Shield colorectal cancer screening. The company's stock has seen significant gains, with a 64.65% return over 90 days and 171.85% over the past year. While a popular narrative suggests the stock is 6% undervalued with a fair value of $171 per share, its current P/S ratio of 18.3x is considerably higher than the US Healthcare industry average of 1.5x, raising valuation risk concerns.
Guardant Health (NASDAQ: GH) insider plans August sale of 116 shares
Musa Tariq, an insider at Guardant Health, Inc. (NASDAQ: GH), has filed a Form 144 notice to sell 116 shares of common stock, valued at $18,148.00, on or after August 17, 2026. These shares originated from a Restricted Stock Lapse related to equity compensation on July 15, 2026. The filing also details several prior sales of Guardant Health stock by Tariq over the preceding three months.
GSA Capital Partners LLP Makes New $1.77 Million Investment in Guardant Health, Inc. $GH
GSA Capital Partners LLP has made a new investment of $1.77 million in Guardant Health, Inc. by purchasing 11,811 shares during the second quarter. Despite significant insider selling totaling over $106 million in the last three months, institutional investors collectively own 92.60% of the company. Guardant Health maintains a "Moderate Buy" consensus rating from analysts, with several firms raising their price targets, indicating a positive outlook for the company's stock.
SWS Partners Makes New Investment in Guardant Health, Inc. $GH
SWS Partners has acquired a new stake in Guardant Health, Inc. (NASDAQ:GH), purchasing 74,582 shares valued at approximately $11.19 million, making it their 9th largest position. While institutional investors collectively own 92.6% of the company, several insiders have recently sold shares totaling over $106 million. Analysts maintain a "Moderate Buy" rating with an average price target of $183.78 for Guardant Health.
